ISSN: 2155-6105
Journal of Addiction Research & Therapy
黑料网
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 4859
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- SafetyLit
- China National Knowledge Infrastructure (CNKI)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Improving clinical outcomes for management of heroin and alcohol dependence using sustained release naltrexone
7th International Conference on Addictive Disorders and Alcoholism
Gary Hulse
University of Western Australia, Australia
Posters & Accepted Abstracts: J Addict Res Ther
DOI:
Abstract
Oral naltrexone has been used effectively to manage problem opiate and alcohol use but patient noncompliance limits its utility. Over the past decade an increasing body of research has suggested that the use of sustained release depot naltrexone preparations can overcome this issue and deliver improved clinical outcomes. These preparations commonly involve the use of naltrexone polymer/co-polymer base formulations administered subcutaneously or intramuscularly and depending on the formulation and mode of administration can deliver levels of blood naltrexone between 30 to 180 days. At the same time, research findings from pharmacogenetics has also converged to identify variables including genetic markers and drug use history differences that play a major role in mediating the response to treatment by naltrexone. The establishment of clinical procedures to maximize use of oral and sustained release formulations, and characterization of clinical markers to identify those patients who are most likely to benefit from naltrexone will ultimately provide significant benefit to both patients and clinicians by optimizing treatment outcome.Biography
Email: Gary.Hulse@uwa.edu.au
